source
- Regeneron immunotherapy combo comes up short in melanoma trialA two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…BioPharma Dive · 2mo ago↗ source
- Texas is opening up a detransition clinicAmericans exposed to Ebola outbreak, Bill Cassidy's primary defeat, and more health news from Morning RoundsSTAT · 2mo ago↗ source
- Unlocking more value from mature drug products through strategic outsourcingSee how strategic outsourcing can maximize value and reduce costs for mature drug portfolios.BioPharma Dive · 2mo ago↗ source